首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1446825

全球笔针市场 - 2024-2031

Global Pen Needles Market - 2024-2031

出版日期: 2024年02月13日 | 出版商:

DataM Intelligence | 英文 206 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球笔针市场达35亿美元，预计2031年将达85亿美元，2024-2031年预测期间CAGR为11.8%。

随着越来越多的糖尿病患者普遍使用胰岛素，全球笔用针头市场的需求不断成长。製造商推出了各种创新功能，例如超细针头、增强的安全机制和改进的注射技术。

笔式针头为患者提供了一种便捷的胰岛素剂量管理方式，无需任何医疗保健专业人员的帮助。糖尿病自我照护和自我管理趋势的增加导致对笔针的需求增加。这些进步提高了使用笔针的便利性和安全性，让患者使用起来更加舒适。

北美是全球笔用针头市场的成长地区之一，由于其医疗设施的崛起和医疗技术的高度采用，涵盖了大量的市场区域。该地区的糖尿病患者不断增加，人口不断增长推动了市场需求。这些地区的政府采取了各种倡议，以提高人们对笔针市场进步的认识。

笔用针头市场见证了技术的持续发展。与其他地区相比，亚太地区的成长最快，人口也相对较多。中国、日本和印度的笔用针消费量大幅成长，这些国家的消费量也随之增加。例如，2022 年 9 月 9 日，全球医疗产业领导者 Terumo India 宣布为需要注射胰岛素的患者推出 FineGlide。

动力学

慢性病盛行率不断上升

糖尿病、心血管疾病、癌症等慢性病明显增加。从而增加了笔针市场的需求。这些疾病需要定期用药，目前通常使用笔式註射器来完成。笔式註射器已成为注射药物传输结构的标准，因为它们易于使用并且可以由受影响的人直接给药而无需任何外部帮助。

例如，2018年11月14日，HMD为糖尿病患者推出Dispovan笔针胰岛素，印度有7,400万人患有糖尿病。 Hindustan 注射器和医疗设备公司是一次性注射器的领先製造商，并推出了 dispovan 胰岛素针头，这项进步将推动笔式针头市场的成长。

糖尿病需要定期注射胰岛素来维持血糖水平。。智慧胰岛素笔提供剂量追踪、提醒和与智慧型手机应用程式连接等功能，帮助个人保持胰岛素治疗方案的正常进行。透过促进用药依从性，智慧胰岛素笔有助于更好的疾病管理和改善健康结果。

例如，2023 年 3 月 14 日，智慧胰岛素笔是可重复使用的注射笔，可帮助糖尿病患者更轻鬆地管理病情。这些笔与智慧型手机应用程式配合使用，简化了计算血糖水平、胰岛素剂量和膳食量的过程。透过自动化糖尿病管理中涉及的数学，智慧胰岛素笔减轻了患有糖尿病症状的个人所面临的一些挑战。

对替代药物传输模式的偏好

一些消费者对针头有恐惧或厌恶，这导致他们寻求替代的药物输送方法。它可以包括胰岛素帮浦、吸入器或口服药物等技术。这些替代方案的可用性可能会影响对笔针的需求，特别是对于优先考虑无针注射的个人而言。

药物传递技术的不断进步可能为胰岛素给药带来新的、更方便的选择。例如，研究人员正在探索微针贴片、植入式装置和吸入式胰岛素製剂的使用。事实证明，替代技术更加用户友好、高效，这将促进市场的成长。

笔式针头通常比胰岛素帮浦等替代药物输送设备便宜，但糖尿病管理的整体成本仍然是个人的重要因素。考虑到保险范围和财务状况等因素，一些患者会寻求可节省成本或具有更好长期价值的替代方法。

例如，研究人员发现了一种基于植物的胰岛素调节系统，其中含有三种胜肽。在植物胰岛素中，植物细胞在材料分解成微生物之前保护胰岛素免受酸的侵害。研究人员从各个方面探索了这些植物胰岛素，例如生产用作胰岛素样化合物的植物蛋白质的基因工程植物。

胰岛素注射笔针的局限性

笔针有不同的长度和尺寸，范围从 4 毫米到 8 毫米。适当的针长取决于体型、皮下脂肪厚度和个人喜好等因素。然而，皮下脂肪较厚的个体可能会发现用较短的针长度有效注射胰岛素具有挑战性，因为胰岛素可能无法到达所需的组织深度。

轮换注射部位以避免脂肪肥大并确保胰岛素吸收的一致性至关重要。然而，重复使用相同的注射部位可能会导致疤痕组织形成和胰岛素吸收不一致。有些人可能会发现由于可用区域有限，很难持续轮换注射部位。

笔式针头可提供准确的剂量输送，但剂量测量中仍可能出现人为错误。对于个人来说，仔细遵循剂量说明并在註射前仔细检查剂量至关重要。处理不当或测量不正确可能导致剂量过量或不足，可能影响血糖控制。

安全处理用过的笔针对于防止意外针刺伤害和污染非常重要。适当的处置方案可能并不总是容易获得，特别是在旅行或在公共场所时。它需要负责任的处置实践，以确保个人和社区的安全。

Pen needles offer a convenient way for patients to administer their insulin doses without the need for any healthcare professionals. The increase in the trend towards self-care and self-management of diabetes has led to an increase demand for pen needles. The advancements improved the convenience and safety of using pen needles, which makes them more comfortable to use by patients.

North America is among the growing regions in the global pen needles market and covers a large area of the market due to its rise in medical facilities and high adoption of medical technologies. The region has witnessed increasing diabetes patients and a growing population drives the demand for the market. Government in these region adapts various initiatives to create awareness about the advancement that pen needles market offers.

Continuous growth in technology is witnessed in the pen needles market. Asia-Pacific witnessed the highest growth and the population is comparatively high compared to other regions. China, Japan and India witnessed major growth, as consumption of pen needles increased in these countries. For instance, on, 9 Sept 2022, Terumo India a global leader in the medical industry announced the launch of FineGlide for patients who requires insuline injections.

Dynamics

Growing Prevalence of Chronic Diseases

Chronic diseases such as diabetes, cardiovascular disease and cancer significantly increased. Thus increasing demand of pen needle market. The diseases require regular administration of drugs, which is now typically done using pen injectors. Pen injectors have emerged as the norm for injectable drug delivery structures because of the reality that they are easy to apply and may be administered directly by the affected person without any external assistance.

For instance, on 14 Nov 2018, HMD launches Dispovan pen needle insulin for diabetic patients, India witnessed 74 million people suffering from diabetics. Hindustan syringes and medical devices is a leading manufacture of disposable syringes and launched its dispovan insulin needles this advancement will boost the growth of pen needles market.

Diabetes requires regular insulin administration to maintain blood sugar levels. . Smart insulin pens offer features such as dose tracking, reminders and connectivity to smartphone apps, which help individuals stay on track with their insulin regimen. By promoting medication adherence, smart insulin pens contribute to better disease management and improved health outcomes.

For instance, 14 March 2023, on Smart insulin pens are reusable injector pens that help individuals with diabetes manage their condition more easily. The pens work alongside a smartphone app, which simplifies the process of calculating blood sugar levels, insulin dosage and meal sizes. By automating the maths involved in diabetes management, smart insulin pens alleviate some of the challenges faced by individuals experiencing diabetes symptoms.

Preference for Alternative Modes of Drug Delivery

Some consumers have a fear or aversion to needles that leads them to seek alternative methods of drug delivery. It can include technologies such as insulin pumps, inhalers or oral medications. The availability of these alternative options can impact the demand for pen needles, particularly among individuals who prioritize needle-free administration.

Ongoing advancements in drug delivery technologies may introduce new and more convenient options for insulin administration. For example, researchers are exploring the use of microneedle patches, implantable devices and inhalable insulin formulations. The alternative technologies prove to be more user-friendly, efficient these will boost the growth of the market.

Pen needles are generally more affordable than alternative drug delivery devices like insulin pumps, the overall cost of diabetes management can still be a significant factor for individuals. Factors such as insurance coverage and financial situations, some patients go for alternative methods that offer cost savings or better long-term value.

For instance, Researchers found a plant-based insulin-regulated system that contains three peptides. In plant-based insulin, plant cell protect insulines from acids before materials brokes into microbes. Researchers explored these plant based insuline in various aspects such genetically enegineering plants that produce plant-based protein used as insulin-like compound.

Limitations of Pen Needles in Insulin Administration

Pen needles are available in different lengths and sizes, in which ranging starts from 4mm to 8mm. The appropriate needle length depends on factors such as body size, subcutaneous fat thickness and individual preferences. However, individuals with thicker subcutaneous fat may find it challenging to effectively inject insulin with shorter needle lengths, as the insulin may not reach the desired tissue depth.

It is essential to rotate injection sites to avoid lipohypertrophy and ensure consistent insulin absorption. However, using the same injection sites repeatedly can lead to scar tissue formation and inconsistent insulin absorption. Some individuals may find it difficult to consistently rotate injection sites due to limited areas available.

Pen needles provide accurate dose delivery, but human error in dose measurement can still occur. It is crucial for individuals to carefully follow instructions for dosing and to double-check the dosage before injection. Mishandling or incorrect measurement can lead to over- or under-dosing, potentially impacting blood sugar control.

Disposing of used pen needles safely is important to prevent accidental needlestick injuries and contamination. Proper disposal options may not always be readily available, particularly when traveling or in public settings. It requires responsible disposal practices to ensure the safety of individuals and the community.

Segment Analysis

The global pen needles market is segmented based on product, length, therapy, end-user and region.

Rising Safety Pen Needles Demand for Reducing Risk Factors

Safety pen needles are specifically designed to reduce the risk of NSIs and protect both patients and healthcare professionals. The rising number of individuals diagnosed with diabetes has significantly increased the demand for insulin administration devices. As more individuals require insulin therapy, the need for safe and effective needle options becomes critical.

For instance, 27 Jun 2023, Tracey sainsbury discuss that how diabetes is increasing, In 2010 EU directives introduced safety pens. Safety pen needles in insulin administration is crucial for patient safety and the prevention of needlestick injuries. Safety pen needles come in two types: active and passive. Active safety devices show the needle throughout the injection process, requiring the user to manually activate the safety mechanism. Passive safety devices cover the needle before and after the injection, but it may obstruct the visibility of the needle.

Impact of Pen Needles in Hospital

The compact and portable design of pen needles makes them suitable for use in hospitals where mobility and space are often limited. The simplicity of pen needle usage allows for quick and accurate insulin administration, which ensures effective diabetes management for patients. The factors lead to an increase in the growth of needle markets from the hospital sector.

The prevalence of diabetes among patients who were hospitalized witnessed 12% to 26%. A study found that around 2000 patients were diagnosed with hyperglycemia at the time of hospital admission. As insulin pens are cost-effective when compared to traditional injections, so this factor makes them the preferred choice for hospitals.

Geographical Penetration

North American Manages Diabetes with Pen Needle Market

The North American pen needles market has witnessed significant growth because the rise in diabetic patients created an alarming situation in the nation, a report by national diabetes statistics that the diabetes case rise up to 37.3 million. The region has carbonated drinks and foods that have high sugar consumption these factors increase diabetes which leads to an increase in the pen needles market.

For instance, on 28 Dec 2022, research conducted by JAMA open network finds that consumers with diabetes are still experiencing increments in blood sugar levels. For managing insulin therapy patients are commonly using insulin pens that provide more convenient options compared to syringes. Pen needles ensure safety and minimize the risk of infections.

Rapid Growth of Pen Needles Due to Increasing Population

Asia-Pacific has a major growth rate in the consumption of pen needles market. Countries like China, Japan and India witnessed increases in demand due to urbanization and growing population leading to increasing consumption of pen needles in these countries. The region heavily invested in healthcare infrastructure, including medical facilities and services. The enhances the availability and distribution of pen needles that, includes hospitals, clinics and pharmacies.

For instance, on 10 Jul 2023, According to the international diabetes federation the adult population witnessed 10.5% of people having diabetes, due to their living conditions. Around 42.5% of people suffer from diabetes in Delhi and every third person in the house, these factors increase the use of pen needle insulins as they are easy to handle.

COVID-19 Impact Analysis

The pandemic highlighted the importance of chronic health conditions, including diabetes. As individuals with diabetes are considered at higher risk for COVID-19 infection, there has been a growing emphasis on effective diabetes management, including insulin administration using pen needles.

The government-imposed lockdowns and restrictions on the movement and minimized hospitals because of their chance to affected by infection, many individuals have transitioned to home-based care. The shift has led to an increased demand for pen needles, as they are easy to use at home and allow for self-administration of insulin.

The pandemic has disrupted global supply chains, that affect the production and distribution of medical devices, including pen needles. Manufacturers have faced challenges in sourcing raw materials and maintaining production levels that lead to temporary shortages in some regions. The factors affect the growth of the pen needles market.

During a pandemic, there has been an increased focus on infection control and needlestick injuries. The has led to a higher demand for safety pen needles, which incorporate safety mechanisms to reduce the risk of accidental needlestick injuries and enhance patient and healthcare provider safety.

Scope

By Product

Standard Pen Needles
Safety Pen Needles

By Length

4 mm
5 mm
6 mm
8 mm
10 mm
12 mm

By Therapy

Insulin Therapy
Glucagon-Like Peptide-1
Growth Hormone Therapy
Other Therapies

By End-User

Hospitals
Diagnostic Centers
Ambulatory Surgery Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Russia
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Middle East and Africa

Key Developments

On 9 May 2022, Roche Diabetes launches ACCU-Fine pen needles for painless delivery of insulin, which includes a 33G 4mm variant. It have main three key features that ensure comfort to consumer and easy to use.
On 25 May 2022, Owen Mumford announces that the safety pen needle will join unifine safe control brand. The provides safety and control and also protects from needlestick injuries.
On 4 Nov 2022, Walgreens announces its partnership which expands access to complimentary diabetes. Walgreens aims to contribute to better disease management and improved health outcomes for the diabetes community.

Competitive Landscape

The major global players include Becton, Dickinson and Company, Novo Nordisk A/S, B. Braun Melsungen AG, Owen Mumford, Terumo Corporation, Nipro Corporation, Allison Medical, AdvaCare Pharma, Berpu Medical Technology, Trividia Health.

Why Purchase the Report?

To visualize the global pen needles market segmentation based on product, length, therapy, end-user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Pen Needles market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global pen needles market report would provide approximately 69 tables, 71 figures and 206 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Lenght
3.3. Snippet by Therapy
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing Prevalence of Chronic Diseases
  - 4.1.1.2. Preference for Alternative Modes of Drug Delivery
- 4.1.2. Restraints
  - 4.1.2.1. Limitations of Pen Needles in Insulin Administration
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Standard Pen Needles *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Safety Pen Needles

8. By Length

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 8.1.2. Market Attractiveness Index, By Length
8.2. 4 mm*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. 5 mm
8.4. 6 mm
8.5. 8 mm
8.6. 10 mm
8.7. 12 mm

9. By Therapy

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 9.1.2. Market Attractiveness Index, By Therapy
9.2. Insulin Therapy *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Glucagon-Like Peptide-1
9.4. Growth Hormone Therapy
9.5. Other Therapies

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Ambulatory Surgery Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Russia
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Becton, Dickinson and Company*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Novo Nordisk A/S
13.3. B. Braun Melsungen AG
13.4. Owen Mumford
13.5. Terumo Corporation
13.6. Nipro Corporation
13.7. Allison Medical
13.8. AdvaCare Pharma
13.9. Berpu Medical Technology
13.10. Trividia Health

LIST NOT EXHAUSTIVE